Basic Information
| LncRNA/CircRNA Name | CCAL |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Oxaliplatin, 5-FU | |
| Variant | Cell Growth | Circulating | 2 | ||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | Microarray, qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP |
| Sample | Human CRC cell lines SW480 and HCT 116, human embryonic kidney cells HEK293T, colorectal cancer tissues, paired adjacent non-cancerous tissue |
| Expression Pattern | up-regulated |
| Function Description | we show that lncRNA CCAL (colorectal cancer associated lncRNA) promotes oxaliplatin resistance of CRC cells. RNA-ISH shows higher CCAL expressed in the tumor stroma compared with cancer nests of CRC tissues. Functional studies reveal that CCAL is transferred from CAFs to the cancer cells via exosomes, where it suppresses CRC cell apoptosis, confers chemoresistance and activates ?-catenin pathway in vitro and in vivo. Mechanistically, CCAL interacts directly with mRNA stabilizing protein HuR (human antigen R) to increase ?-catenin mRNA and protein levels. |
| Pubmed ID | 31381140 |
| Year | 2019 |
| Title | Long non-coding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells |
External Links
| Links for CCAL | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |